News

The Lexington News Issue #1 — Q3/2017

Welcome the the “Lexington News” where we hope to inform you on our ongoing efforts to develop our HeartSentry device into a revolutionary, simple and effective technology for personalized measurement and monitoring of vascular health. Aimed at detecting the potential for cardiovascular disease at its earliest stages, we are working to commercialize HeartSentry as part

Read More

Lexington Biosciences Announces Private Placement

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA – August 8 , 2017 – Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, is pleased to announce a non-brokered private placement of up to

Read More

Lexington Biosciences Announces Closing of Private Placement

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES  VANCOUVER, BC – (July 28, 2017) – Lexington Biosciences, Inc. (CSE: LNB)( OTC: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, is pleased to announce, further to its news release of

Read More

Lexington Biosciences Announces DTC Eligibility of LXGTF Common Shares on OTCQB

VANCOUVER, BC–(Jul 25, 2017) – Lexington Biosciences, Inc. (CSE: LNB) (CNSX: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, is pleased to announce it has received processing approval from The Depository Trust Company (“DTC”) of New York, NY and is now DTC eligible. The Depository Trust Company (DTC) is a subsidiary

Read More

Lexington Biosciences Introduces Medical Advisory Board

Advisory team prepares to move HeartSentry through clinical studies VANCOUVER, BC–(Jul 20, 2017) – Lexington Biosciences, Inc. (CSE: LNB) (CNSX: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, in preparation for the commencement of its HeartSentry clinical studies, today wishes to introduce the members of its Medical Advisory Board. The growing

Read More

Lexington Biosciences Commences Trading on OTC Markets as LXGTF and Introduces Key Board Members

VANCOUVER, BC–(Jul 6, 2017) – Lexington Biosciences, Inc. (CSE: LNB) (CNSX: LNB) (OTC PINK: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, is pleased to announce it has met the compliance requirements of the Financial Industry Regulatory Authority (FINRA) and has initiated price quotation on OTC Link under the ticker symbol: LXGTF. In

Read More

Lexington Biosciences Commences Trading on Canadian Securities Exchange (CSE: LNB)

VANCOUVER, BC–(May 9, 2017) –  Lexington Biosciences, Inc. (CSE: LNB)  (the “Company” or “Lexington“), a development-stage medical device company operating within the healthcare industry, is pleased to announce that the Company has commenced trading on the Canadian Securities Exchange (the “Exchange“) effective May 9, 2017 under the symbol “LNB.” Transaction and Private Placement The Company

Read More

What’s the No. 1 killer of Americans?

Story highlight Heart disease and cancer are the top two killers of Americans (CNN)The leading causes of death remained the same from the year before: Heart disease is the No. 1 killer, followed by cancer, according to the U.S. Centers for Disease Control and Prevention, and infant mortality decreased 2.3%. But there is good news

Read More

Archives

Categories

Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News